{"id":26627,"date":"2026-04-13T10:02:23","date_gmt":"2026-04-13T10:02:23","guid":{"rendered":"https:\/\/readtrends.com\/en\/immunotherapy-eliminating-cancers\/"},"modified":"2026-04-13T10:02:23","modified_gmt":"2026-04-13T10:02:23","slug":"immunotherapy-eliminating-cancers","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/immunotherapy-eliminating-cancers\/","title":{"rendered":"\u2018It\u2019s incredible \u2014 like science fiction\u2019: A new wave of immunotherapy is eradicating cancers"},"content":{"rendered":"<article>\n<p>Over the past decade immunotherapy \u2014 treatments that rally the patient\u2019s own immune system to attack tumours \u2014 has moved from promise to practice, producing complete remissions in some previously incurable cancers. In a recent clinical programme at Memorial Sloan Kettering Cancer Center, 71\u2011year\u2011old Maureen Sideris received 45\u2011minute infusions of the checkpoint inhibitor dostarlimab every three weeks and, after four months, her oesophageal tumour vanished without surgery, chemotherapy or radiation; her principal treatment toxicity was adrenal insufficiency causing fatigue. That result sits alongside 2022 and 2024 trials that showed dramatic tumour regressions in rectal cancer and an expanded cohort of 117 patients with varied tumour types sharing a particular genetic signature. Researchers say these findings mark an inflection point: durable, sometimes curative responses are now achievable for subsets of patients, even as most cancers remain resistant.<\/p>\n<h2>Key takeaways<\/h2>\n<ul>\n<li>The 2018 Nobel Prize recognised the science behind immune checkpoint inhibitors, which are now used across many tumour types.<\/li>\n<li>CAR T\u2011cell therapies, effective mainly in blood cancers, and checkpoint inhibitors are the leading immunotherapy platforms today, but each has limits.<\/li>\n<li>Overall response rates to current immunotherapies typically fall in the 20\u201340% range, leaving a majority of patients without benefit.<\/li>\n<li>In MSK\u2019s expanded study of tumours with a specific genetic profile, 103 patients completed treatment and 84 experienced complete disappearance of their tumours; only two required subsequent surgery.<\/li>\n<li>Only about 5% of tumours carry the genetic features that predict a surgery\u2011free response to the particular checkpoint strategy studied, underscoring the need for broader approaches.<\/li>\n<li>Adverse events can range from mild (rashes, diarrhoea, fatigue) to rare but serious organ inflammation (liver, heart, kidneys), per the US National Cancer Institute.<\/li>\n<li>Multimodal tactics \u2014 combining immunotherapy with radiation, ultrasound, microbiome modulation or low\u2011cost drugs such as statins \u2014 are under study to increase the proportion of responders.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>Concepts of immune surveillance date back nearly a century, but only in recent decades have tools matured that reliably harness the immune system against cancer. Two major clinical successes have emerged: CAR T\u2011cell therapies, which reprogramme a patient\u2019s T cells in the lab to target tumour antigens, and immune checkpoint inhibitors, drugs that disable inhibitory brakes on T cells so they can attack tumours. The checkpoint approach earned its pioneers the Nobel Prize in 2018 and has since been approved across multiple cancer types.<\/p>\n<p>Despite those advances, important gaps remain. CAR T therapies have shown outstanding results in certain blood cancers but have struggled to penetrate solid tumours, which account for more than 90% of new cancer diagnoses. Checkpoint inhibitors can provoke a wide array of immune\u2011related side effects because they reduce the immune system\u2019s built\u2011in restraints; and, crucially, no current immunotherapy benefits every patient \u2014 response rates commonly hover between 20% and 40% depending on cancer type and biomarker profile.<\/p>\n<h2>Main event<\/h2>\n<p>The clinical examples attracting attention include patients treated with checkpoint blockade at Memorial Sloan Kettering. Maureen Sideris, treated there for oesophageal cancer with dostarlimab, received 45\u2011minute infusions every three weeks and experienced complete tumour disappearance within four months. Her experience \u2014 tumour eradication without surgery, chemo or radiation \u2014 highlights the potential for immune drugs to provide organ\u2011preserving, life\u2011saving outcomes.<\/p>\n<p>MSK\u2019s investigators initially reported exceptional responses in small 2022 and 2024 rectal cancer studies among tumours with a mismatch\u2011repair\u2011deficient or hypermutated genetic profile. They then opened an expanded cohort enrolling 117 patients with oesophageal, bladder, stomach and other tumours that shared the same predictive signature. Of the 103 patients who finished the planned course, 84 had complete responses and only two later needed surgery, a striking rate of organ\u2011sparing remissions in that selected group.<\/p>\n<p>Other centres have produced similar, though smaller, signals using different checkpoint agents. MD Anderson researchers reported outcomes consistent with the idea that specific genetic or immunological tumour features can predict unusually robust responses. Meanwhile, investigators are testing combinations \u2014 adding radiation or ultrasound to make tumours more immunogenic, and exploring how diet, microbiome changes and widely available drugs such as statins might amplify benefit.<\/p>\n<h2>Analysis &amp; implications<\/h2>\n<p>These results shift the conversation from incremental improvement to rethinking standard practice for some patients. Where surgery, chemotherapy or radiotherapy have been the default curative tools, immunotherapy now offers a pathway to organ preservation and lower long\u2011term morbidity in genetically selected cases. If validated in larger, randomized studies, this could reduce life\u2011altering surgeries such as rectal, bladder or stomach removals for a subset of patients.<\/p>\n<p>However, the gains are uneven. The MSK expansion depended on a molecular signature present in roughly 5% of tumours; the remaining 95% still require new strategies. That reality creates acute research priorities: broaden the spectrum of targetable tumour features, reduce toxicity, and make effective treatments affordable and scalable. CAR T approaches, for instance, must be adapted to penetrate solid\u2011tumour microenvironments, and checkpoint strategies must become safer for wider use.<\/p>\n<p>Economics and access pose parallel challenges. Many immunotherapies are costly to manufacture and deliver. Even when clinical benefit is clear, uneven global access and payer decisions will determine whether breakthroughs translate into population\u2011level survival gains. Policymakers, providers and industry will need to align on pricing, trial diversity and infrastructure so that effective immunotherapies do not remain available only to a privileged few.<\/p>\n<h2>Comparison &amp; data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Approach<\/th>\n<th>Primary target<\/th>\n<th>Typical response<\/th>\n<th>Key limitation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>CAR T\u2011cell therapy<\/td>\n<td>Engineered T cells vs blood cancer antigens<\/td>\n<td>High in certain leukemias\/lymphomas<\/td>\n<td>Poor penetration of solid tumours; complex manufacturing<\/td>\n<\/tr>\n<tr>\n<td>Checkpoint inhibitors<\/td>\n<td>PD\u20111\/PD\u2011L1, CTLA\u20114 pathways<\/td>\n<td>20\u201340% overall; higher in biomarker\u2011positive tumours<\/td>\n<td>Immune\u2011related adverse events; variable efficacy<\/td>\n<\/tr>\n<tr>\n<td>Dostarlimab (MSK cohort)<\/td>\n<td>PD\u20111 blockade in genetically selected tumours<\/td>\n<td>84 complete responses of 103 completers in expanded cohort<\/td>\n<td>Applicable to ~5% of tumours with that signature<\/td>\n<\/tr>\n<tr>\n<td>Cancer vaccines (personalised)<\/td>\n<td>Patient\u2011specific tumour antigens<\/td>\n<td>Promising early signals (e.g., small kidney and melanoma studies)<\/td>\n<td>Early\u2011phase data; logistical complexity<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>The table summarises broad performance and limitations. While checkpoint drugs offer a widely applicable mechanism, their benefit concentrates in tumours with specific molecular or immunological profiles. CAR T is a proven paradigm in hematologic malignancies but needs evolution to treat the solid\u2011tumour majority. Personalised vaccines and combination regimens aim to expand the fraction of patients who achieve durable remissions.<\/p>\n<h2>Reactions &amp; quotes<\/h2>\n<p>Clinicians and patients have responded with a mix of awe and cautious optimism, stressing both the human impact and the need for rigorous follow\u2011up.<\/p>\n<blockquote>\n<p>&#8220;It&#8217;s unbelievable \u2014 almost like science fiction,&#8221;<\/p>\n<p><cite>Maureen Sideris, patient (Memorial Sloan Kettering trial participant)<\/cite><\/p><\/blockquote>\n<p>Sideris\u2019 remark underscores the contrast between decades of invasive treatments and the possibility of non\u2011surgical cures for some patients. Clinician reactions emphasise both emotional weight and scientific significance.<\/p>\n<blockquote>\n<p>&#8220;People are living, and living with good quality lives,&#8221;<\/p>\n<p><cite>Jennifer Wargo, surgical oncology &amp; immunotherapy researcher, MD Anderson<\/cite><\/p><\/blockquote>\n<p>Wargo highlights that successful immunotherapy can produce durable survival with preserved function. Other experts stress that the current breakthroughs are biomarker\u2011driven and that broader applicability will require additional discovery and validation.<\/p>\n<blockquote>\n<p>&#8220;We have to move from Medieval times to modern times,&#8221;<\/p>\n<p><cite>Luis Diaz, head of solid tumour oncology, Memorial Sloan Kettering<\/cite><\/p><\/blockquote>\n<p>Diaz framed the clinical aim: reduce reliance on mutilating surgery where immune\u2011based cures are possible, while acknowledging that most tumours still lack predictive features for such outcomes.<\/p>\n<aside>\n<details>\n<summary>Explainer \u2014 how checkpoint inhibitors and CAR T cells differ<\/summary>\n<p>Checkpoint inhibitors are drugs that block inhibitory signals (such as PD\u20111\/PD\u2011L1) that cancer cells use to switch off T cells; by removing that brake, T cells can attack tumours. CAR T therapy physically engineers a patient\u2019s own T cells to recognise a tumour\u2011specific antigen, expanding the immune system\u2019s targeting precision. Checkpoint drugs are systemically delivered pills or infusions and have broad applicability but variable efficacy; CAR T is personalised cell therapy with high potency in some blood cancers but substantial logistical and delivery hurdles for solid tumours. Both approaches can cause immune\u2011related toxicities and are the focus of combination and enhancement strategies.<\/p>\n<\/details>\n<\/aside>\n<h2>Unconfirmed<\/h2>\n<ul>\n<li>Whether inexpensive statins reliably boost immunotherapy efficacy remains under investigation and is not yet proven in randomized phase III trials.<\/li>\n<li>Early\u2011day dosing improving outcomes has shown signal in limited studies but needs larger validation before changing scheduling practices.<\/li>\n<li>Claims that chemotherapy and radiation will be obsolete within ten years are speculative and depend on broadening effective options well beyond the ~5% of tumours currently highlighted by MSK\u2019s genetic\u2011signature results.<\/li>\n<\/ul>\n<h2>Bottom line<\/h2>\n<p>Immunotherapy has entered a new phase in which, for carefully selected patients, it can deliver durable remissions and even apparent cures without surgery or conventional cytotoxic treatments. The MSK experience with dostarlimab in tumours carrying a predictive genetic signature provides one of the clearest examples: rapid, complete responses and the prospect of organ preservation for a meaningful minority of patients.<\/p>\n<p>That said, most cancers do not yet carry the molecular features that predict such dramatic benefit. The path forward is to expand the population that can be helped \u2014 through combination therapies, vaccine strategies, microbiome and metabolic modulation, and better biomarkers \u2014 while keeping safety, cost and access at the centre of clinical and policy discussions. If those barriers are addressed, immunotherapy could reshape cancer care over the coming decade; until then, the progress is transformative for some and aspirational for many.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.bbc.com\/future\/article\/20260410-how-a-new-wave-of-immunotherapy-is-eliminating-cancers\" target=\"_blank\" rel=\"noopener\">BBC Future \u2014 feature on emerging immunotherapy results (media)<\/a><\/li>\n<li><a href=\"https:\/\/www.mskcc.org\/\" target=\"_blank\" rel=\"noopener\">Memorial Sloan Kettering Cancer Center \u2014 institutional news and clinical trial descriptions (clinical\/academic)<\/a><\/li>\n<li><a href=\"https:\/\/www.mdanderson.org\/\" target=\"_blank\" rel=\"noopener\">MD Anderson Cancer Center \u2014 oncology research summaries (academic\/clinical)<\/a><\/li>\n<li><a href=\"https:\/\/www.dana-farber.org\/\" target=\"_blank\" rel=\"noopener\">Dana\u2011Farber Cancer Institute \u2014 research and personalised vaccine studies (academic\/clinical)<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\" target=\"_blank\" rel=\"noopener\">US National Cancer Institute \u2014 overview of immunotherapy and side effects (official\/educational)<\/a><\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Over the past decade immunotherapy \u2014 treatments that rally the patient\u2019s own immune system to attack tumours \u2014 has moved from promise to practice, producing complete remissions in some previously incurable cancers. In a recent clinical programme at Memorial Sloan Kettering Cancer Center, 71\u2011year\u2011old Maureen Sideris received 45\u2011minute infusions of the checkpoint inhibitor dostarlimab every &#8230; <a title=\"\u2018It\u2019s incredible \u2014 like science fiction\u2019: A new wave of immunotherapy is eradicating cancers\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/immunotherapy-eliminating-cancers\/\" aria-label=\"Read more about \u2018It\u2019s incredible \u2014 like science fiction\u2019: A new wave of immunotherapy is eradicating cancers\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":26626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"A new wave of immunotherapy is eradicating cancers \u2014 OnPoint","rank_math_description":"Clinical trials show immunotherapy producing complete remissions for selected patients. MSK results with dostarlimab and emerging vaccine strategies hint at less invasive, potentially curative care.","rank_math_focus_keyword":"immunotherapy,dostarlimab,cancer vaccines,CAR T,checkpoint inhibitors","footnotes":""},"categories":[2],"tags":[],"class_list":["post-26627","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/26627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=26627"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/26627\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/26626"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=26627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=26627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=26627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}